PortfoliosLab logo
IBRN vs. IDNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between IBRN and IDNA is 0.58, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

IBRN vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Neuroscience and Healthcare ETF (IBRN) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

IBRN:

-0.18

IDNA:

-0.51

Sortino Ratio

IBRN:

0.08

IDNA:

-0.47

Omega Ratio

IBRN:

1.01

IDNA:

0.94

Calmar Ratio

IBRN:

-0.06

IDNA:

-0.17

Martin Ratio

IBRN:

-0.16

IDNA:

-0.95

Ulcer Index

IBRN:

12.87%

IDNA:

11.70%

Daily Std Dev

IBRN:

26.88%

IDNA:

24.95%

Max Drawdown

IBRN:

-35.39%

IDNA:

-68.26%

Current Drawdown

IBRN:

-21.56%

IDNA:

-61.91%

Returns By Period

In the year-to-date period, IBRN achieves a -11.89% return, which is significantly lower than IDNA's -9.40% return.


IBRN

YTD

-11.89%

1M

-3.88%

6M

-17.49%

1Y

-4.70%

3Y*

N/A

5Y*

N/A

10Y*

N/A

IDNA

YTD

-9.40%

1M

-2.65%

6M

-16.29%

1Y

-12.72%

3Y*

-9.49%

5Y*

-9.87%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


IBRN vs. IDNA - Expense Ratio Comparison

Both IBRN and IDNA have an expense ratio of 0.47%.


Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

IBRN vs. IDNA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IBRN
The Risk-Adjusted Performance Rank of IBRN is 1313
Overall Rank
The Sharpe Ratio Rank of IBRN is 1010
Sharpe Ratio Rank
The Sortino Ratio Rank of IBRN is 1414
Sortino Ratio Rank
The Omega Ratio Rank of IBRN is 1414
Omega Ratio Rank
The Calmar Ratio Rank of IBRN is 1212
Calmar Ratio Rank
The Martin Ratio Rank of IBRN is 1313
Martin Ratio Rank

IDNA
The Risk-Adjusted Performance Rank of IDNA is 55
Overall Rank
The Sharpe Ratio Rank of IDNA is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of IDNA is 55
Sortino Ratio Rank
The Omega Ratio Rank of IDNA is 55
Omega Ratio Rank
The Calmar Ratio Rank of IDNA is 88
Calmar Ratio Rank
The Martin Ratio Rank of IDNA is 55
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

IBRN vs. IDNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Neuroscience and Healthcare ETF (IBRN) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current IBRN Sharpe Ratio is -0.18, which is higher than the IDNA Sharpe Ratio of -0.51. The chart below compares the historical Sharpe Ratios of IBRN and IDNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

IBRN vs. IDNA - Dividend Comparison

IBRN's dividend yield for the trailing twelve months is around 0.45%, less than IDNA's 1.09% yield.


TTM202420232022202120202019
IBRN
iShares Neuroscience and Healthcare ETF
0.45%0.40%0.05%0.00%0.00%0.00%0.00%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.09%0.98%1.04%0.54%0.70%0.26%0.80%

Drawdowns

IBRN vs. IDNA - Drawdown Comparison

The maximum IBRN drawdown since its inception was -35.39%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for IBRN and IDNA.


Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

IBRN vs. IDNA - Volatility Comparison

iShares Neuroscience and Healthcare ETF (IBRN) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) have volatilities of 9.62% and 9.70%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...